

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Sunil Chada *et al.*

Serial No.: 10/791,692

Filed: March 2, 2004

For: METHODS AND COMPOSITIONS
INVOLVING MDA-7

Group Art Unit: 1743

Examiner: Nagpaul, Jyoti

Atty. Dkt. No.: INGN:105US

Confirmation No.: 3897

**CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8**

I hereby certify that this correspondence is being
electronically filed with the United States Patent and
Trademark Office via EFS-Web on the date below:

March 2, 2007

Date

Monica A. De La Paz

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:105US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz
Reg. No. 54,662
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 2, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:105US	Serial No.: 10/791,692
List of Patents and Publications for Applicant's		Applicant: Sunil Chada <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: March 2, 2004	Group: 1743
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C280	Bocangel <i>et al.</i> , "Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells," <i>Cancer Gene Therapy</i> , 1-11, 2006.
	C281	Chada <i>et al.</i> , "mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biological therapies and radiotherapy: correlation with expression of bcl-2 family members," <i>Cancer Gene Therapy</i> , 1-13, 2005.
	C282	Emdad <i>et al.</i> , "Ionizing Radiation Enhances Adenoviral Vector Expressing mda-7/IL-24-mediated Apoptosis in Human Ovarian Cancer," <i>J. Cell Physiol.</i> , 208:298-306, 2006.
	C283	Inoue <i>et al.</i> , "MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic," <i>Current Gene Therapy</i> , 6:73-91, 2006.
	C284	Kawabe <i>et al.</i> , "Adenovirus-Mediated mda-7 Gene Expression Radiosensitizes Non-Small Cell Lung Cancer Cells via TP53-Independent Mechanisms," <i>Molecular Therapy</i> , 6:637-644, 2002.
	C285	McKenzie <i>et al.</i> , "Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells," <i>Surgery</i> , 136:437-442, 2004.
	C286	Nishikawa <i>et al.</i> , "Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells," <i>Oncogene</i> , 23:7125-7131, 2004.
	C287	Nishikawa <i>et al.</i> , "Adenovirus-Mediated mda-7 (IL24) Gene Therapy Suppresses Angiogenesis and Sensitizes NSCLC Xenograft Tumors to Radiation," <i>Mol. Therapy</i> , 9:818-828, 2004.

25751356.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:105US	Serial No.: 10/791,692
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: March 2, 2004	Group: 1743
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C288	Su <i>et al.</i> , "Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2," <i>Oncogene</i> , 25:2339-2348, 2006.

25751356 1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)